249 related articles for article (PubMed ID: 23934828)
1. Sulfoximines: a neglected opportunity in medicinal chemistry.
Lücking U
Angew Chem Int Ed Engl; 2013 Sep; 52(36):9399-408. PubMed ID: 23934828
[TBL] [Abstract][Full Text] [Related]
2. Application of sulfoximines in medicinal chemistry from 2013 to 2020.
Han Y; Xing K; Zhang J; Tong T; Shi Y; Cao H; Yu H; Zhang Y; Liu D; Zhao L
Eur J Med Chem; 2021 Jan; 209():112885. PubMed ID: 33227576
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of Sulfoximine Carbamates by Rhodium-Catalyzed Nitrene Transfer of Carbamates to Sulfoxides.
Zenzola M; Doran R; Luisi R; Bull JA
J Org Chem; 2015 Jun; 80(12):6391-9. PubMed ID: 25989821
[TBL] [Abstract][Full Text] [Related]
4. Novel Pieces for the Emerging Picture of Sulfoximines in Drug Discovery: Synthesis and Evaluation of Sulfoximine Analogues of Marketed Drugs and Advanced Clinical Candidates.
Sirvent JA; Lücking U
ChemMedChem; 2017 Apr; 12(7):487-501. PubMed ID: 28221724
[TBL] [Abstract][Full Text] [Related]
5. Increasing Complexity: A Practical Synthetic Approach to Three-Dimensional, Cyclic Sulfoximines and First Insights into Their in Vitro Properties.
Boulard E; Zibulski V; Oertel L; Lienau P; Schäfer M; Ganzer U; Lücking U
Chemistry; 2020 Apr; 26(19):4378-4388. PubMed ID: 31961028
[TBL] [Abstract][Full Text] [Related]
6. The lab oddity prevails: discovery of pan-CDK inhibitor (R)-S-cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide (BAY 1000394) for the treatment of cancer.
Lücking U; Jautelat R; Krüger M; Brumby T; Lienau P; Schäfer M; Briem H; Schulze J; Hillisch A; Reichel A; Wengner AM; Siemeister G
ChemMedChem; 2013 Jul; 8(7):1067-85. PubMed ID: 23671017
[TBL] [Abstract][Full Text] [Related]
7. C-C bond-forming desulfurizations of sulfoximines.
Reggelin M; Slavik S; Bühle P
Org Lett; 2008 Sep; 10(18):4081-4. PubMed ID: 18712875
[TBL] [Abstract][Full Text] [Related]
8. N-Trifluoromethylthiolated Sulfoximines.
Bohnen C; Bolm C
Org Lett; 2015 Jun; 17(12):3011-3. PubMed ID: 26029817
[TBL] [Abstract][Full Text] [Related]
9. Exploring the reactivity of N-alkynylated sulfoximines: [2 + 2]-cycloadditions.
Pirwerdjan R; Priebbenow DL; Becker P; Lamers P; Bolm C
Org Lett; 2013 Nov; 15(21):5397-9. PubMed ID: 24151931
[TBL] [Abstract][Full Text] [Related]
10. Sulfoximines from a Medicinal Chemist's Perspective: Physicochemical and in vitro Parameters Relevant for Drug Discovery.
Frings M; Bolm C; Blum A; Gnamm C
Eur J Med Chem; 2017 Jan; 126():225-245. PubMed ID: 27821325
[TBL] [Abstract][Full Text] [Related]
11. New Opportunities for the Utilization of the Sulfoximine Group in Medicinal Chemistry from the Drug Designer's Perspective.
Lücking U
Chemistry; 2022 Oct; 28(56):e202201993. PubMed ID: 35789054
[TBL] [Abstract][Full Text] [Related]
12. Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors.
Dwyer MP; Paruch K; Alvarez C; Doll RJ; Keertikar K; Duca J; Fischmann TO; Hruza A; Madison V; Lees E; Parry D; Seghezzi W; Sgambellone N; Shanahan F; Wiswell D; Guzi TJ
Bioorg Med Chem Lett; 2007 Nov; 17(22):6216-9. PubMed ID: 17904366
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and Transformations of NH-Sulfoximines.
Andresini M; Tota A; Degennaro L; Bull JA; Luisi R
Chemistry; 2021 Dec; 27(69):17293-17321. PubMed ID: 34519376
[TBL] [Abstract][Full Text] [Related]
14. A critical electrostatic interaction mediates inhibitor recognition by human asparagine synthetase.
Ikeuchi H; Meyer ME; Ding Y; Hiratake J; Richards NG
Bioorg Med Chem; 2009 Sep; 17(18):6641-50. PubMed ID: 19683931
[TBL] [Abstract][Full Text] [Related]
15. C(1)-symmetric sulfoximines as ligands in copper-catalyzed asymmetric Mukaiyama-type aldol reactions.
Langner M; Bolm C
Angew Chem Int Ed Engl; 2004 Nov; 43(44):5984-7. PubMed ID: 15547912
[No Abstract] [Full Text] [Related]
16. Design and synthesis of sulfoximine based inhibitors for HIV-1 protease.
Raza A; Sham YY; Vince R
Bioorg Med Chem Lett; 2008 Oct; 18(20):5406-10. PubMed ID: 18829317
[TBL] [Abstract][Full Text] [Related]
17. Bioactive sulfoximines: syntheses and properties of Vioxx analogs.
Park SJ; Buschmann H; Bolm C
Bioorg Med Chem Lett; 2011 Aug; 21(16):4888-90. PubMed ID: 21752640
[TBL] [Abstract][Full Text] [Related]
18. Recent developments with boron as a platform for novel drug design.
Leśnikowski ZJ
Expert Opin Drug Discov; 2016 Jun; 11(6):569-78. PubMed ID: 27080414
[TBL] [Abstract][Full Text] [Related]
19. Sulfoximines as Rising Stars in Modern Drug Discovery? Current Status and Perspective on an Emerging Functional Group in Medicinal Chemistry.
Mäder P; Kattner L
J Med Chem; 2020 Dec; 63(23):14243-14275. PubMed ID: 32870008
[TBL] [Abstract][Full Text] [Related]
20. The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing.
Jones CD; Andrews DM; Barker AJ; Blades K; Daunt P; East S; Geh C; Graham MA; Johnson KM; Loddick SA; McFarland HM; McGregor A; Moss L; Rudge DA; Simpson PB; Swain ML; Tam KY; Tucker JA; Walker M
Bioorg Med Chem Lett; 2008 Dec; 18(24):6369-73. PubMed ID: 18996007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
